Prospects for the use of mesenchymal stromal cells in the treatment of dilated cardiomyopathy
Authors:
- Zekhra E. MirzezadeZMZekhra E. Mirzezade
- Olga V. PayushinaOPOlga V. Payushina
- Dibakhan A. TsomartovaDTDibakhan A. Tsomartova
- Yelizaveta V. ChereshnevaYelizaveta V. Chereshneva
- Nataliya L. KartashkinaNKNataliya L. Kartashkina
- Elina S. TsomartovaETElina S. Tsomartova
- Svetlana A. KosobutskayaSKSvetlana A. Kosobutskaya
Open Access
- 10 March 2026
- journal article
- Published by ECO-Vector LLC (Publications) in Genes & Cells
- Vol. 21 (1) , 5-16
Abstract
This review discusses the mechanisms underlying the therapeutic effects and the clinical prospects of mesenchymal stromal cell (MSC) transplantation in dilated cardiomyopathy. The development of dilated cardiomyopathy is based on a complex interplay of multiple etiological factors and mechanisms. This condition is characterized by high prevalence, unfavorable prognosis, and substantial mortality, highlighting the need for innovative treatment methods. In dilated cardiomyopathy, mesenchymal stromal cells exert multifaceted effects on the injured myocardium, primarily through paracrine secretion of cytoprotective, immunomodulatory, proangiogenic, and antifibrotic factors; suppression of oxidative stress; and restoration of cardiomyocyte energy metabolism. Preclinical and clinical studies have demonstrated the ability of mesenchymal stromal cells to improve cardiac contractile function and patients’ quality of life. Sustained long-term benefits have been reported, with allogeneic cells showing greater therapeutic potential and a lower incidence of complications compared with autologous cells. To enhance the efficacy of MSC transplantation and facilitate its broader implementation in clinical practice, several challenges must be addressed, including optimization of cell sources, delivery methods, and strategies to improve cell survival within the hostile myocardial microenvironment. In this context, genetic modification of mesenchymal stromal cells aimed at enhancing their cardioprotective and regenerative properties represents a promising approach to improving outcomes in patients with dilated cardiomyopathy.Keywords
This publication has 52 references indexed in Scilit:
- The Application of Mesenchymal Stem Cells in Different Cardiovascular Disorders: Ways of Administration, and the EffectorsStem Cell Reviews and Reports, 2024
- Therapeutic effects of erythropoietin expressed in mesenchymal stem cells for dilated cardiomyopathy in ratBiochemical and Biophysical Research Communications, 2019
- Intravenous mesenchymal stem cell-derived exosomes ameliorate myocardial inflammation in the dilated cardiomyopathyBiochemical and Biophysical Research Communications, 2018
- Concise Review: Multifaceted Characterization of Human Mesenchymal Stem Cells for Use in Regenerative MedicineStem Cells Translational Medicine, 2017
- Fibrosis of extracellular matrix is related to the duration of the disease but is unrelated to the dynamics of collagen metabolism in dilated cardiomyopathyInflammation Research, 2016
- Mesenchymal stem cells attenuate inflammatory processes in the heart and lung via inhibition of TNF signalingBasic Research in Cardiology, 2016
- Allogeneic Mesenchymal Stem Cells Restore Endothelial Function in Heart Failure by Stimulating Endothelial Progenitor CellsEBioMedicine, 2015
- Impact of repeated intravenous bone marrow mesenchymal stem cells infusion on myocardial collagen network remodeling in a rat model of doxorubicin-induced dilated cardiomyopathyMolecular and Cellular Biochemistry, 2013
- Human Mesenchymal Stem Cells Reprogram Adult Cardiomyocytes Toward a Progenitor-Like State Through Partial Cell Fusion and Mitochondria TransferStem Cells, 2011
- Dilated cardiomyopathy is associated with an increase in the type I/type III collagen ratio: A quantitative assessmentJACC, 1995